{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:08:04Z","timestamp":1772471284177,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012467.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000}}],"reference-count":108,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012467.pub3","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T12:38:32Z","timestamp":1607949512000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy"],"prefix":"10.1002","volume":"2020","author":[{"given":"Hiraku","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Hospital Care Research Unit; Hyogo Prefectural Amagasaki General Medical Center; Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology; School of Public Health in the Graduate School of Medicine, Kyoto University; Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Mathematics; Shimane University; Matsue Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology; School of Public Health in the Graduate School of Medicine, Kyoto University; Kyoto Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence (CiRC2LE); Fukushima Medical University; Fukushima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Anesthesia; Shiga University of Medical Science Hospital; Otsu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Hyogo Prefectural Amagasaki General Medical Center; Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2010.01.048","article-title":"Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter","volume":"126","author":"Arcangeli","year":"2010","journal-title":"Thrombosis Research"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01694706","article-title":"Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study","volume":"19","author":"Bellomo","year":"1993","journal-title":"Intensive Care Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD012467.pub3-BIB0003|cit3","first-page":"24A","article-title":"Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]","volume":"17","author":"Betjes","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012467.pub3-BIB0004|cit4","first-page":"602","article-title":"Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding","volume":"20","author":"Betjes","year":"2007","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/08860220601166222","article-title":"Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study","volume":"29","author":"Birnbaum","year":"2007","journal-title":"Renal Failure"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s13054-014-0472-6","article-title":"Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial","volume":"18","author":"Schilder","year":"2014","journal-title":"Critical Care (London, England)"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2369-15-19","article-title":"Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients","volume":"15","author":"Schilder","year":"2014","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12882-015-0167-5","article-title":"Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities","volume":"16","author":"Schilder","year":"2015","journal-title":"BMC Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/cc13838","article-title":"The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied","volume":"18","author":"Schilder","year":"2014","journal-title":"Critical Care (London, England)"},{"issue":"52","key":"10.1002\/14651858.CD012467.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"e2392","DOI":"10.1097\/MD.0000000000002392","article-title":"Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial","volume":"94","author":"Choi","year":"2015","journal-title":"Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012467.pub3-BIB0011|cit11","first-page":"1884","article-title":"The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification","volume":"32","author":"Cui","year":"2011","journal-title":"Journal of Qiqihar University of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00003246-200002000-00022","article-title":"Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study","volume":"28","author":"Pont","year":"2000","journal-title":"Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1399-6576.2009.02031.x","article-title":"Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study","volume":"54","author":"Fabbri","year":"2010","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/039139880703000404","article-title":"A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration","volume":"30","author":"Fealy","year":"2007","journal-title":"International Journal of Artificial Organs"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1441-2772(23)01454-0","article-title":"Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial","volume":"16","author":"Brain","year":"2014","journal-title":"Critical Care & Resuscitation"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/08860221003606281","article-title":"Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial","volume":"32","author":"Garces","year":"2010","journal-title":"Renal Failure"},{"issue":"8","key":"10.1002\/14651858.CD012467.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/CCM.0000000000001004","article-title":"A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults","volume":"43","author":"Gattas","year":"2015","journal-title":"Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1081\/JDI-120039529","article-title":"Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy","volume":"26","author":"Hein","year":"2004","journal-title":"Renal Failure"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/ndt\/gfq575","article-title":"Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial","volume":"26","author":"Hetzel","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD012467.pub3-BIB0020|cit20","first-page":"728","article-title":"Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]","volume":"14","author":"Joannidis","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD012467.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00134-007-0719-7","article-title":"Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study","volume":"33","author":"Joannidis","year":"2007","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0022|cit22","unstructured":"Kountchev J Grote A Bellmann R Wiedermann C Joannidis M Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 384"},{"issue":"11","key":"10.1002\/14651858.CD012467.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1592\/phco.30.11.1117","article-title":"Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy","volume":"30","author":"Kiser","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0024|cit24","first-page":"96","article-title":"Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial","volume":"114","author":"Kozek-Langenecker","year":"2002","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/j.1523-1755.2005.00342.x","article-title":"Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients","volume":"67","author":"Kutsogiannis","year":"2005","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD012467.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/00003246-199422110-00012","article-title":"Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration","volume":"22","author":"Langenecker","year":"1994","journal-title":"Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012467.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"e108737","DOI":"10.1371\/journal.pone.0108737","article-title":"Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012467.pub3-BIB0028|cit28","first-page":"i425","article-title":"The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]","volume":"28","author":"Lee","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/cc6998","article-title":"Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study","volume":"12","author":"Link","year":"2008","journal-title":"Critical Care (London, England)"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","article-title":"Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study","volume":"30","author":"Monchi","year":"2004","journal-title":"Intensive Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","article-title":"Citrate anticoagulation for continuous venovenous hemofiltration","volume":"37","author":"Oudemans-van Straaten","year":"2009","journal-title":"Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00002480-199541040-00006","article-title":"Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy","volume":"41","author":"Palevsky","year":"1995","journal-title":"ASAIO Journal"},{"issue":"10","key":"10.1002\/14651858.CD012467.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1097\/00003246-199910000-00026","article-title":"A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration","volume":"27","author":"Reeves","year":"1999","journal-title":"Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0034|cit34","first-page":"203","article-title":"Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]","volume":"21","author":"Reeves","year":"2003","journal-title":"Blood Purification"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-015-0822-z","article-title":"Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial","volume":"19","author":"Stucker","year":"2015","journal-title":"Critical Care (London, England)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012467.pub3-BIB0036|cit36","first-page":"S320","article-title":"Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]","volume":"39","author":"Stucker","year":"2013","journal-title":"Intensive Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1744-9987.2011.00996.x","article-title":"Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration","volume":"15","author":"Tiranathanagul","year":"2011","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000083938","article-title":"Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation","volume":"23","author":"Voort","year":"2005","journal-title":"Blood Purification"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0039|cit39","unstructured":"van Doorn KJ Hubloue I Verbeelen D Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 384"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0040|cit40","first-page":"243","article-title":"Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]","volume":"22","author":"Doorn","year":"2004","journal-title":"Blood Purification"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s001340100907","article-title":"Hirudin versus heparin for anticoagulation in continuous renal replacement therapy","volume":"27","author":"Vargas Hein","year":"2001","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0042|cit42","unstructured":"Victorino JA Otero E Rohsig L Dornelles E Louzada M Stifft J Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128] American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA) 2007"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000381662","article-title":"Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration","volume":"39","author":"Wu","year":"2015","journal-title":"Blood Purification"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0044|cit44","unstructured":"Zhang K Gong D Ji D Xu B IIu Z Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71] CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA) 2012"},{"issue":"5","key":"10.1002\/14651858.CD012467.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s13054-014-0588-8","article-title":"Argatroban versus lepirudin in critically ill patients (Alicia): a randomized controlled trial","volume":"18","author":"Treschan","year":"2014","journal-title":"Critical Care (London, England)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012467.pub3-BIB0046|cit46","first-page":"32","article-title":"Changes in respiratory parameters in patients with severe multiple trauma with continuous haemofiltration [abstract no: 118]","volume":"19","author":"Ambr\u00c3\u0083\u00c2\u00b3s Checa","year":"1995","journal-title":"Medicina Intensiva"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012467.pub3-BIB0047|cit47","first-page":"101","article-title":"Depuration capacity of thromboxane A2 in continuous haemofiltration in patients with severe multiple trauma [abstract no: 345]","volume":"20","author":"P\u00c3\u0083\u00c2\u00a9rez Vela","year":"1996","journal-title":"Medicina Intensiva"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012467.pub3-BIB0048|cit48","first-page":"63","article-title":"Depuration capacity of leukotriene B4 in continuous haemofiltration in patients with severe multiple trauma [abstract no: 210]","volume":"20","author":"S\u00c3\u0083\u00c2\u00a1nchez-Izquierdo Riera","year":"1996","journal-title":"Medicina Intensiva"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000446979","article-title":"A comparison between two dilute citrate solutions (15 vs. 18 mmol\/l) in continuous renal replacement therapy: the Base Excess and Renal Substitution Solution study","volume":"42","author":"Anstey","year":"2016","journal-title":"Blood Purification"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0050|cit50","unstructured":"Henriksson BA Evaluation of lifespan in AN69ST with two different heparinization strategies www.isrctn.com\/ISRCTN01121161"},{"issue":"7","key":"10.1002\/14651858.CD012467.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/00003246-199807000-00021","article-title":"Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration","volume":"26","author":"Kozek-Langenecker","year":"1998","journal-title":"Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/01.CCM.0000055374.77132.4D","article-title":"Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration","volume":"31","author":"Kozek-Langenecker","year":"2003","journal-title":"Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/MAT.0b013e31815cc3bf","article-title":"Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration","volume":"54","author":"Lafargue","year":"2008","journal-title":"ASAIO Journal"},{"issue":"11","key":"10.1002\/14651858.CD012467.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/BF01709346","article-title":"Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration","volume":"22","author":"Leslie","year":"1996","journal-title":"Intensive Care Medicine"},{"issue":"S1","key":"10.1002\/14651858.CD012467.pub3-BIB0055|cit55","first-page":"194","article-title":"The comparing research of anticoagulation with sodium citrate or heparin in continuous venovenous hemodiafiltration","volume":"27","author":"Lin","year":"2007","journal-title":"Chinese Journal of Practical Internal Medicine"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0056|cit56","unstructured":"Jansen van Doorn KJ Verpooten G Verbrugghe W Jorens P Comparison of slow efficiency daily dialysis (SLEDD) with unfractionated heparin versus citrasate in critically ill patients www.clinicaltrials.gov\/ct2\/show\/NCT01228292"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0057|cit57","unstructured":"Golper TA Sika M A comparison of dilute versus concentrated heparin for CRRT anticoagulation www.clinicaltrials.gov\/ct2\/show\/NCT01318811"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0058|cit58","unstructured":"Boer W Magnesium balance of citrate-based continuous venovenous hemofiltration, effect of citrate dose www.clinicaltrials.gov\/ct2\/show\/NCT02194569"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/039139880202500606","article-title":"The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration","volume":"25","author":"Polanska","year":"2002","journal-title":"International Journal of Artificial Organs"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"R193","DOI":"10.1186\/cc8191","article-title":"Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates","volume":"13","author":"Oudemans-van Straaten","year":"2009","journal-title":"Critical Care (London, England)"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0061|cit61","first-page":"193","article-title":"Albumin priming does not prolong hemofilter life","volume":"43","author":"Reeves","year":"1997","journal-title":"ASAIO Journal"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0062|cit62","first-page":"226","article-title":"A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial","volume":"15","author":"Robinson","year":"2014","journal-title":"Trials [Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF01704703","article-title":"Heparin clearance during continuous veno-venous haemofiltration","volume":"20","author":"Singer","year":"1994","journal-title":"Intensive Care Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012467.pub3-BIB0064|cit64","first-page":"iii220","article-title":"Safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis [abstract no: SP442]","volume":"29","author":"Tingli","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0065|cit65","first-page":"449","article-title":"Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial","volume":"15","author":"Bruyere","year":"2014","journal-title":"Trials [Electronic Resource]"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0066|cit66","first-page":"240","article-title":"A study of the dosage of argatroban for anticoagulation effect in the patients undergoing high volume hemofiltration","volume":"21","author":"Wang","year":"2009","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue [Chinese Critical Care Medicine]"},{"issue":"12","key":"10.1002\/14651858.CD012467.pub3-BIB0067|cit67","first-page":"953","article-title":"Evaluation of the application of regional citrate anticoagulation in sustained low efficiency hemodialysis","volume":"53","author":"Wang","year":"2014","journal-title":"Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0068|cit68","unstructured":"Srisawat N Immunomodulation effect of regional citrate anticoagulation in acute kidney injury requiring continuous renal replacement therapy www.clinicaltrials.gov\/ct2\/show\/NCT02423642"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0069|cit69","unstructured":"Kim DK Circuit survival and efficacy for middle molecular-weight solute elimination between nafamostat infusion and heparinized saline priming www.clinicaltrials.gov\/ct2\/show\/NCT01486485"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0070|cit70","unstructured":"Regional citrate versus systemic heparin anticoagulation for super high-flux continuous hemodialysis in septic shock: effect on middle molecular weight molecules clearances www.clinicaltrials.gov\/ct2\/show\/NCT01839578"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0071|cit71","unstructured":"Zarbock A Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury www.clinicaltrials.gov\/ct2\/show\/NCT02669589"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0072|cit72","unstructured":"Arcaroli J Clinical evaluation of use of prismocitrate 18 in patients undergoing acute continuous renal replacement therapy (CRRT) www.clinicaltrials.gov\/ct2\/show\/NCT02860130"},{"issue":"12","key":"10.1002\/14651858.CD012467.pub3-BIB0073|cit73","first-page":"309","article-title":"Hospitalization discharge diagnoses for kidney disease - United States 1980-2005","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR - Morbidity & Mortality Weekly Report"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0074|cit74","unstructured":"Davenport A Anticoagulation for continuous renal replacement therapy UpToDate 2018 Topic 16855 Version 12.0"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1036-7314(06)80026-3","article-title":"Maintaining the CRRT circuit: non-anticoagulant alternatives","volume":"19","author":"Davies","year":"2006","journal-title":"Australian Critical Care"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.04120413","article-title":"Subacute kidney injury in hospitalized patients","volume":"9","author":"Fujii","year":"2014","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD012467.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/CCM.0000000000001004","article-title":"A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults","volume":"43","author":"Gattas","year":"2015","journal-title":"Critical Care Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD012467.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD012467.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0081|cit81","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD012467.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ndt\/gfv069","article-title":"Current state of continuous renal replacement therapy for acute kidney injury in Japanese intensive care units in 2011: analysis of a national administrative database","volume":"30","author":"Iwagami","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/cc5937","article-title":"Clinical review: patency of the circuit in continuous renal replacement therapy","volume":"11","author":"Joannidis","year":"2007","journal-title":"Critical Care (London, England)"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney international - Supplement"},{"issue":"1-3","key":"10.1002\/14651858.CD012467.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000485232","article-title":"A continuous renal replacement therapy protocol on the updated Nikkiso Aquarius Platform using regional citrate as first-line anticoagulation significantly improves filter life span but the position of the vascular access is key","volume":"45","author":"Kirwan","year":"2018","journal-title":"Blood Purification"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.ajkd.2014.03.018","article-title":"The daily burden of acute kidney injury: a survey of U.S. nephrologists on World Kidney Day","volume":"64","author":"Koyner","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13054-016-1299-0","article-title":"Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"20","author":"Liu","year":"2016","journal-title":"Critical Care (London, England)"},{"issue":"7","key":"10.1002\/14651858.CD012467.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5301\/IJAO.2011.8535","article-title":"Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study","volume":"34","author":"Maruyama","year":"2011","journal-title":"International Journal of Artificial Organs"},{"issue":"9987","key":"10.1002\/14651858.CD012467.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/S0140-6736(15)60126-X","article-title":"International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology","volume":"6736","author":"Mehta","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00134-012-2796-5","article-title":"Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. [Erratum in: Intensive Care Med. 2013 Apr;39(4):798]","volume":"39","author":"Nisula","year":"2013","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0092|cit92","first-page":"237","volume-title":"Critical Care Medicine: Principles of Diagnosis and Management in the Adult","author":"Parikh","year":"2014"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0093|cit93","first-page":"926","volume-title":"Brenner and Rector's The Kidney","author":"Parikh","year":"2016"},{"issue":"3","key":"10.1002\/14651858.CD012467.pub3-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003773.pub3","article-title":"Intermittent versus continuous renal replacement therapy for acute renal failure in adults","author":"Rabindranath","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"10.1002\/14651858.CD012467.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa0902413","article-title":"Intensity of continuous renal-replacement therapy in critically ill patients","volume":"361","author":"Bellomo","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/B978-1-4377-1367-1.00115-4","volume-title":"Textbook of Critical Care","author":"Ronco","year":"2011"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s13054-014-0472-6","article-title":"Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial","volume":"18","author":"Schilder","year":"2014","journal-title":"Critical Care (London, England)"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0098|cit98","unstructured":"Sch\u00c3\u0083\u00c2\u00bcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012467.pub3-BIB0099|cit99","unstructured":"Sch\u00c3\u0083\u00c2\u00bcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1525-139X.2008.00545.x","article-title":"Anticoagulation for continuous renal replacement therapy","volume":"22","author":"Tolwani","year":"2009","journal-title":"Seminars in Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00134-003-1672-8","article-title":"Continuous is not continuous: the incidence and impact of circuit \"down-time\" on uraemic control during continuous veno-venous haemofiltration","volume":"29","author":"Uchino","year":"2003","journal-title":"Intensive Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012467.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","article-title":"Continuous renal replacement therapy: a worldwide practice survey: the Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators","volume":"33","author":"Uchino","year":"2007","journal-title":"Intensive Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0103|cit103","first-page":"7","article-title":"Intensity of renal support in critically ill patients with acute kidney injury. [Erratum in: N Engl J Med. 2009 Dec 10;361(24):2391]","volume":"359","author":"Palevsky","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012467.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/cc7784","article-title":"Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury","volume":"13","author":"Vesconi","year":"2009","journal-title":"Critical Care (London, England)"},{"issue":"4","key":"10.1002\/14651858.CD012467.pub3-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009631.pub2","article-title":"Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease","author":"Wang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012467.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MCC.0000000000000541","article-title":"Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?","volume":"24","author":"Wang","year":"2018","journal-title":"Current Opinion in Critical Care"},{"issue":"1","key":"10.1002\/14651858.CD012467.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2215\/CJN.02730313","article-title":"Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals","volume":"9","author":"Zeng","year":"2014","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"12","key":"10.1002\/14651858.CD012467.pub3-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012467","article-title":"Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy","author":"Tsujimoto","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T01:52:19Z","timestamp":1698457939000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012467.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":108,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012467.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]}}}